1. Signaling Pathways
  2. Immunology/Inflammation
  3. Galectin


Galectins are a family of proteins that possess β-galactoside-binding properties through their carbohydrate recognition domains (CRDs). Galectins can be secreted from cells by nonclassic pathways to interact with external glycoconjugates and have a variety of activities both extra- and intracellularly, with important implicated roles in immunity, inflammation, and cancer.

Galectins can be classified according to the CRD features. Galectin-1, -2, -5, -7, -10, -11, -13, and -14 are composed of a CRD and a short N-terminal sequence (prototype). Galectin-4, -6, -8, -9, and -12 have two nonidentical CRDs in tandem with a short linker sequence (tandem-repeat type). Galectin-3 has an exceptional structure, with a CRD and an extended N-terminal domainconsisting of gycine/proline-rich repeats and a short N-terminal end (chimera type). Galectin-1 (Gal1), a carbohydrate-binding protein is implicated in cancer cell proliferation, invasion and tumour angiogenesis. Galectin-3 (Gal3) is a β-galactoside binding lectin that is highly expressed in fibrotic tissue of diverse etiologies.

Galectins have emerged as key players in the tumor microenvironment. Galectins are expressed and released by different celltypes, including tumor, stromal, endothelial and immune cells. Galectins critically influence tumor progression by modulating tumor cell migration, invasiveness, angiogenesis and antitumor immune responses. Intracellularly, galectins modulate survival and proliferation and they interact with a variety of signaling pathways. Given these extracellular and intracellular functions and their regulated expression at sites of tumor growth and metastasis, galectins have stimulated great interest as relevant biomarkers and novel targets in cancer therapy.

Galectin Related Products (5):

Cat. No. Product Name Effect Purity
  • HY-114409
    GB1107 Inhibitor 99.73%
    GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.
  • HY-19756
    OTX008 Inhibitor ≥98.0%
    OTX008 is a selective inhibitor of galectin-1.
  • HY-P1592A
    G3-C12 TFA 99.45%
    G3-C12 (TFA) is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
  • HY-130208
    Thiodigalactoside Inhibitor ≥99.0%
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.
  • HY-P1592
    G3-C12 99.44%
    G3-C12 is a galectin-3 binding peptide, with Kd of 88 nM, and shows anticancer activity.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.